CONy 2021 | New migraine targets: AMY1 & PACAP

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, gives an overview of new targets for migraine therapy. A potential new target is the amylin subtype 1 receptor (AMY1), as a recent study has shown that an AMY1 analog, pramlintide, induces migraine-like attacks in patients. Other studies are also investigating pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that probably has a wider role in migraine pathophysiology than calcitonin gene-related peptide (CGRP). Pre-clinical data on this neuropeptide looks promising and monoclonal antibodies targeting PACAP are under development. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).